HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) saw strong trading volume on Wednesday . 105,064 shares changed hands during mid-day trading, an increase of 5% from the previous session's volume of 100,338 shares.The stock last traded at $16.16 and had previously closed at $15.93.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. HSBC downgraded HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Wall Street Zen upgraded HUTCHMED from a "buy" rating to a "strong-buy" rating in a research note on Friday, June 27th.
Get Our Latest Report on HUTCHMED
HUTCHMED Trading Down 2.0%
The business has a 50 day simple moving average of $14.88 and a 200 day simple moving average of $14.68. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.83 and a quick ratio of 2.70.
Institutional Trading of HUTCHMED
Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its position in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after buying an additional 2,255 shares during the last quarter. Public Employees Retirement System of Ohio lifted its position in shares of HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after buying an additional 899 shares during the last quarter. Summit Trail Advisors LLC lifted its position in shares of HUTCHMED by 7.7% in the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock worth $212,000 after buying an additional 1,004 shares during the last quarter. OLD Mission Capital LLC acquired a new stake in shares of HUTCHMED in the fourth quarter worth about $230,000. Finally, Marshall Wace LLP acquired a new stake in shares of HUTCHMED in the fourth quarter worth about $261,000. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.